AFP and hepatocellular carcinoma: Patients with HLA-A*02:01 or HLA-A*02:642 haplotypes with positive immunohistochemical staining for AFP (≥1+ in ≥20% of HCC cells) or positive serum AFP (≥400 ng/mL) were eligible.